3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
58
Neoplasm Metastasis
21
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Brain Neoplasms
8
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Neoplasms
3
Esophageal Neoplasms
3
Advanced Breast Cancer
3
Adenocarcinoma
3
Prostatic Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Gastric Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Solid Tumor
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Interventions
Temozolomide
43
Magnetic Resonance Spectroscopy
41
Radiotherapy
23
Specimen Handling
18
Biopsy
13
X-Rays
10
Radiation
10
trametinib
8
Bevacizumab
8
Nivolumab
7
Blood Specimen Collection
7
olaparib
6
fluorodopa F 18
6
dabrafenib
6
Radiotherapy, Intensity-Modulated
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Lomustine
6
pembrolizumab
5
abemaciclib
5
Standard of Care
5
vorasidenib
4
ulixertinib
4
larotrectinib
4
ivosidenib
4
erdafitinib
4
Surgical Procedures, Operative
4
Dianhydrogalactitol
4
Cyclophosphamide
4
Aminolevulinic Acid
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
trastuzumab deruxtecan
×
1 year
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled